Treatment of Mycobacterium abscessus Complex

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Of the nontuberculous mycobacteria (NTMs) causing lung disease, members of the Mycobacterium abscessus complex (MABc) present a formidable obstacle to successful management. This challenge starts from a poorly understood pathogenesis, continues with complicated subspecies variation in treatment response, and extends to the multidrug-resistant nature of these organisms. The disease often necessitates the use of intravenous therapy, toxic drug combinations, and, in some cases, lung resection. Like many NTMs, MABc treatment requires prolonged therapy with multiple medications, and pulmonary disease in some subspecies can be impossible to eradicate or cure. This disease also represents a frequent and unique problem in certain populations, including cystic fibrosis and lung transplant recipients, and providers who manage such patients should be familiar with how MABc disease influences management. Because of the rising prevalence of the MABc, especially in patients with complicated underlying pulmonary disease, it is increasingly necessary for infectious diseases and pulmonary medicine clinicians to understand the unique aspects of MABc management and understand when to obtain expert consultation in the care of these patients.

Original languageEnglish (US)
Pages (from-to)362-376
Number of pages15
JournalSeminars in Respiratory and Critical Care Medicine
Volume39
Issue number3
DOIs
StatePublished - Jan 1 2018

Fingerprint

Mycobacterium
Lung Diseases
Nontuberculous Mycobacteria
Infectious Disease Medicine
Therapeutics
Pulmonary Medicine
Lung
Poisons
Disease Management
Combination Drug Therapy
Cystic Fibrosis
Patient Care
Referral and Consultation
Population

Keywords

  • bronchiectasis
  • cystic fibrosis
  • Mycobacterium abscessus
  • Mycobacterium abscessus treatment
  • Mycobacterium bolletii
  • Mycobacterium massiliense

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

Treatment of Mycobacterium abscessus Complex. / Strnad, Luke; Winthrop, Kevin.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 39, No. 3, 01.01.2018, p. 362-376.

Research output: Contribution to journalArticle

@article{b2baa19c7b324e05850d12e2e68c4aae,
title = "Treatment of Mycobacterium abscessus Complex",
abstract = "Of the nontuberculous mycobacteria (NTMs) causing lung disease, members of the Mycobacterium abscessus complex (MABc) present a formidable obstacle to successful management. This challenge starts from a poorly understood pathogenesis, continues with complicated subspecies variation in treatment response, and extends to the multidrug-resistant nature of these organisms. The disease often necessitates the use of intravenous therapy, toxic drug combinations, and, in some cases, lung resection. Like many NTMs, MABc treatment requires prolonged therapy with multiple medications, and pulmonary disease in some subspecies can be impossible to eradicate or cure. This disease also represents a frequent and unique problem in certain populations, including cystic fibrosis and lung transplant recipients, and providers who manage such patients should be familiar with how MABc disease influences management. Because of the rising prevalence of the MABc, especially in patients with complicated underlying pulmonary disease, it is increasingly necessary for infectious diseases and pulmonary medicine clinicians to understand the unique aspects of MABc management and understand when to obtain expert consultation in the care of these patients.",
keywords = "bronchiectasis, cystic fibrosis, Mycobacterium abscessus, Mycobacterium abscessus treatment, Mycobacterium bolletii, Mycobacterium massiliense",
author = "Luke Strnad and Kevin Winthrop",
year = "2018",
month = "1",
day = "1",
doi = "10.1055/s-0038-1651494",
language = "English (US)",
volume = "39",
pages = "362--376",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "3",

}

TY - JOUR

T1 - Treatment of Mycobacterium abscessus Complex

AU - Strnad, Luke

AU - Winthrop, Kevin

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Of the nontuberculous mycobacteria (NTMs) causing lung disease, members of the Mycobacterium abscessus complex (MABc) present a formidable obstacle to successful management. This challenge starts from a poorly understood pathogenesis, continues with complicated subspecies variation in treatment response, and extends to the multidrug-resistant nature of these organisms. The disease often necessitates the use of intravenous therapy, toxic drug combinations, and, in some cases, lung resection. Like many NTMs, MABc treatment requires prolonged therapy with multiple medications, and pulmonary disease in some subspecies can be impossible to eradicate or cure. This disease also represents a frequent and unique problem in certain populations, including cystic fibrosis and lung transplant recipients, and providers who manage such patients should be familiar with how MABc disease influences management. Because of the rising prevalence of the MABc, especially in patients with complicated underlying pulmonary disease, it is increasingly necessary for infectious diseases and pulmonary medicine clinicians to understand the unique aspects of MABc management and understand when to obtain expert consultation in the care of these patients.

AB - Of the nontuberculous mycobacteria (NTMs) causing lung disease, members of the Mycobacterium abscessus complex (MABc) present a formidable obstacle to successful management. This challenge starts from a poorly understood pathogenesis, continues with complicated subspecies variation in treatment response, and extends to the multidrug-resistant nature of these organisms. The disease often necessitates the use of intravenous therapy, toxic drug combinations, and, in some cases, lung resection. Like many NTMs, MABc treatment requires prolonged therapy with multiple medications, and pulmonary disease in some subspecies can be impossible to eradicate or cure. This disease also represents a frequent and unique problem in certain populations, including cystic fibrosis and lung transplant recipients, and providers who manage such patients should be familiar with how MABc disease influences management. Because of the rising prevalence of the MABc, especially in patients with complicated underlying pulmonary disease, it is increasingly necessary for infectious diseases and pulmonary medicine clinicians to understand the unique aspects of MABc management and understand when to obtain expert consultation in the care of these patients.

KW - bronchiectasis

KW - cystic fibrosis

KW - Mycobacterium abscessus

KW - Mycobacterium abscessus treatment

KW - Mycobacterium bolletii

KW - Mycobacterium massiliense

UR - http://www.scopus.com/inward/record.url?scp=85051171774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051171774&partnerID=8YFLogxK

U2 - 10.1055/s-0038-1651494

DO - 10.1055/s-0038-1651494

M3 - Article

C2 - 30071551

AN - SCOPUS:85051171774

VL - 39

SP - 362

EP - 376

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 3

ER -